Hämatologie Shortcasts
by Dr. med. Richard Schabath, Dr. med. Andreas Hausmann, Dr. med. Stephan Fuhrmann
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇦🇹AT · Education#723K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1.5K to 5K🎙 ~2x weekly·78 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
3K to 10K🇦🇹100% - Active Followers
Loyal subscribers who consistently listen
900 to 3K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 12 epsHosts
Recent guests
Recent episodes
EHA 2026: Die wichtigsten AML-Updates mit Prof. Dr. Lars Bullinger
Jul 14, 2026
17m 53s
Zwischen ASH und ASCO: Praxisrelevante Updates aus Lymphom, AML und Myelofibrose
Jun 11, 2026
17m 38s
AML – Revolution oder Evolution?
Feb 27, 2026
25m 47s
ASH 2025 - Aggressive B-Zell-Lymphome: Neue Optionen für ältere Patient:innen, Zelltherapien und Monitoring
Feb 5, 2026
17m 48s
ASH 2025 – T-Zell-Lymphome: Neue Targets, frühe Rezidive und klinische Konsequenzen
Jan 19, 2026
29m 11s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/14/26 | acute myeloid leukemiaEHA Congress updates+4 | Prof. Dr. Lars Bullinger | VenetoclaxAzacitidin+8 | — | AMLEHA Congress+5 | — | 17m 53s | ||
| 6/11/26 | LymphomaAML+4 | — | TafasitamabLenalidomid+2 | Pankreaskarzinom | LymphomaAML+5 | — | 17m 38s | ||
| 2/27/26 | AML therapyPARADIGM study+4 | Prof. Dr. Lars Bullinger | AzacitidinVenetoclax+9 | — | AMLAzacitidin+5 | — | 25m 47s | ||
| 2/5/26 | B-Zell-LymphomeZelltherapien+4 | Prof. Malte von Bonin | EpcoritamabR-mini-CHOP+9 | — | B-Zell-LymphomeChemotherapie+4 | — | 17m 48s | ||
| 1/19/26 | T-Zell-Lymphomezielgerichtete Therapieansätze+3 | PD Dr. med. Thomas Weber | CD94 gerichtete AntikörperCAR-T-Zellen+5 | — | T-Zell-LymphomeASH 2025+3 | — | 29m 11s | ||
| 12/19/25 | follikuläres LymphomImmuntherapie+4 | — | EpcoritamabR²+5 | — | Epcoritamabfollikuläres Lymphom+6 | — | 20m 07s | ||
| 12/17/25 | myeloid neoplasmsacute myeloid leukemia+4 | Prof. Dr. med. Thomas Schroeder | GilteritinibSorafenib+4 | — | AMLMDS+6 | — | 32m 39s | ||
| 12/16/25 | CLL therapyASH Meeting+3 | Dr. Othman Al-Sawaf | ASHCLL17+3 | — | CLLBTK-Inhibition+5 | — | 24m 15s | ||
| 12/4/25 | Latebreaking AbstractsCAR-T-Zelltherapien+5 | Lucy FoxSimon Harrison+1 | ASH-KongressIBM DX Study+7 | — | ASH 2025Latebreaker+6 | — | 34m 24s | ||
| 12/2/25 | ASH 2025Hämatologie+4 | Dr. med. Andreas Hausmann | IbrutinibVenetoclax-Obinutuzumab+4 | — | ASH 2025Hämatologie+6 | — | 30m 44s | ||
| 10/30/25 | MastozytoseDiagnosekriterien+5 | Priv.-Doz. Dr. Gregor Hörmann | DGHODocCheck+1 | — | MastozytoseDiagnose+5 | — | 14m 59s | ||
| 10/28/25 | Myeloproliferative NeoplasmsCalreticulin Antibodies+4 | Prof. Dr. Haifa Kathrin Al-Ali | Hämatologie ShortcastsDocCheck+1 | — | Myeloproliferative NeoplasmsCalreticulin Antibodies+5 | — | 13m 40s |
Showing 12 of 12
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for Hämatologie Shortcasts
Peaked at #72 in AT, currently #72 in AT.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| AT | — | #72 | #72 | — |
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.